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The detection by direct immunofluorescence of subep-
idermal immune deposits in clinically normal skin of 
patients with systemic lupus erythematosus has become 
known as a positive lupus band test (LET). To gain a 
better understanding of the relation between the LET 
and prognosis in systemic lupus erythematosus (SLE) a 
prospective longitudinal study has been carried out in 
51 SLE patients covering a 10-year period. A total of 
223 LETs were obtained from clinically normal skin of 
the medial volar forearm on these 51 patients (average, 
4.4 per patient) and the results correlated with clinico-
pathologic features of the disease and outcome. Findings 
from the initial LET (obtained while on no systemic 
therapy) were used to divide patients into LET-positive 
and LET-negative groups. With the exception of pa-
tients subsequently treated with daily doses of predni-
sone greater than 40 mg or cytotoxic agents, the patients 
in the LET-positive group usually remained LET-posi-
tive. The LET-negative patients usually remained LET-
negative on repeated testing. A comparison of clinical 
features in the two groups revealed a 55% prevalence 
of lupus nephropathy in the LET-positive group as op-
posed to 23% in the LET-negative group (p = 0 .025). 
Although the two groups had similar serum creatinine 
levels at the time of the initial LET, the maximum serum 
creatinine (mean, 3.0 mg/dl) in the LET-positive group 
was significantly higher than the maximum (mean, 1.2 
mg/dl) in the LET-negative group (p = 0 .04). Further-
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Abbreviations: 
ANA: antinuclear antibody 
BUN: blood urea nitrogen 
CH,.o: complement hemolytic activity 50% 
ESR: erythrocyte sedimentation rate 
KB: a human epidermoid carcinoma-derived cell line 
LBT: lupus band test 
nDNA: native deoxyribonucleic ac id (double-stranded DNA ) 
PBS: phosphate-buffered saline 
SLE: systemic lupus erythematosus 
VORL: Venereal Disease Research Laborato ries 
more, only 9 % of renal biopsies in the LET-negative 
group showed diffuse proliferative glomerulonephritis 
in contrast to 65% of biopsies in the LET -positive group 
(p = 0.007). Lastly, the two groups were compared with 
regard to outcome; 10-year survival from the time of 
diagnosis was 95% in the LET-negative group as op-
posed to only 54% in the LET-positive group (p = 
0.007) . These findings indicate that a positive LET has 
predictive value in that it identifies a subset of SLE 
patients with more aggressive renal disease and signif-
icantly decreased long-term survival. 
Patients with system ic lupus e rythematosus (SLE) m ay have 
subepiderma l immune deposits in clinically normal skin, i.e., a 
positive lupus band test (LBT). There is general a greement 
that a positive LBT is valuable in establishing a diagnosis of 
SLE [1). However, the re lation between a positive LBT and 
prognosis in SLE remains controvers ia l [2- 15). Conflicting 
results of previous s tudies may stem from the failure to meet 
one or more of the fo llowing criteria: adequate number of 
patients, uniformity in patient selection, un iform ity of skin 
biopsy s ite, atte ntion to effects of t herapy, adequate assessment 
of renal histology, and adequate period of fo ll ow-up. To gain a 
better understanding of t he re lation between the LBT and 
prognosis, a prospective 10-year longitudinal study has been 
carried out in 51 consecutive SLE patients. In this report we 
examine t he variabi lity of serial LBT resu lts and t he effec t of 
immunosuppressive t he rapy on the LBT. We a lso present our 
findings regarding the relation between the initial LET, clinical 
features of the d isease during the period of fo llow-up, and 
outcome. 
MATERIALS AND METHODS 
Patients 
Since 1971 , using standard direct immunofluorescence techniques, 
we have examined biopsies from clinically normal, relatively light-
protected, medial volar forearm skin of 24 1 patients with SLE. Fifty-
one of these patients were biopsied either before t reatment or during 
periods when they had been off all forms of systemic treatment for at 
least 6 weeks. These 51 patients were consecutively entered into a 
prospective 10-year longitudinal study during which they were biopsied 
on at least 2 occasions. All 51 patients had a minimum of 4 of the 14 
preliminary American Rheumatism Association crite ria for the classi-
fication of SLE [16]. Forty- fi ve of the patients were women (88%); 37 
were black, 12 were white, and 2 were Hispanic. The mean age at 
diagnosis was 33 years (range, 6- G<I) ; the average t ime between diag-
nosis of SLE and initial LBT was 2.1 years (0- 27). The mean number 
of serial LBTs was 4.4 (2- 9) and the average follow-up since initial 
LBT was 7.4 years (0- 10). All 51 patients were seen by one of us (J G) 
as inpatients at Parkland Memorial Hospital (PMH) or in the outpa-
tient clinics of PMH or the University of Texas Health Science Center 
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at Dallas. Pertinent clinical and laboratory data as well as t herapy 
were r ecorded at each visit. 
Skin Biopsies and !rnmun.ofluorescent Studies 
Punch biopsies of clinically normal skin were obtained from the 
medial volar forea rm . During the initial years of the study (1971 - 1975) 
specimens were immersed in Tissue-Tek (Ames Co., E lkhart, Indiana) , 
and immediately frozen in liquid nit rogen. After 1975, biopsy specimens 
were first placed in chilled 0.01 M phosphate-buffered saline (PBS) , 
pH 7.2, and kept at 4' C for 12- 24 h. This modification was found not 
to diminish the sta ining of immune deposits at the dermal-epidermal 
junction whi le at the same time it reduced the amount of nonspecific 
backgrou nd dermal staining. The specimens were t hen t ransferred to 
% dram cylindrica l polyvinyl vials (Electro Sonic Components, Haw· 
thorne, California), immersed in Tissue-Tek, and immediate ly frozen 
in liquid nit rogen and stored at -70' C until processing, usually within 
2-3 days after the biopsies were obtained. 
Four-l'm cryostat sections were stained with specific fluorescein· 
conj ugated goat ant ihuman JgG , lgA, lgM, and C3 (Meloy Laboratories, 
Sprin gfield, Virginia) diluted 1:10 with PBS [6). All sections were 
examined by one of us (JNG) using an Ortholux fluorescence micro-
scope with epi-illuminat ion (E. Leitz, Inc. , Rockleigh, New J ersey). 
Sections of skin from normal individuals and from patients with known 
pos itive LBTs were employed routinely as negative and positive con· 
trois , respectively. A positive LBT was defined by the presence of 1 or 
more classes of immunoglobulin (lg) along the dermal-epidermal junc-
tion. 
Renal Biopsies 
Tissue adequate for in te rpretation was obtained during renal biopsy 
in 31 patients near the t ime of the first LBT. These represented all 
consenting patients wi th clinical evidence of active renal disease based 
on t h e presence of 2 or more of the following: microscopic hematuria 
and/or cylindruria on 2 or more occasions; 24-h urinary protein excre· 
tio n over 1000 mg; elevated serum creatinine and blood urea nitrogen 
(BUN); and creatinine clearance less than 80 mlfmin. Biopsies were 
classified acco rding to light and electron microscopic findin gs into the 
fo llowi n g categories: diffuse proliferative glomerulonephri tis, membra-
nous g lomerulonephri t is, mesa ngial glomerulitis, or normal. 
The histologic criteria used for this classification were as follows. (a) 
Diffuse proliferative glomerulonephri tis: proliferative lesions involving 
both end othelial and mesangial cells accompanied by cellular necrosis, 
fibrino id change, wire loops, or hematoxylin bodies; closure of the 
capillary loops and distortion of the mesangial areas. (b) Membranous 
glomerulonephritis: widespread t hickening of the glomerular basement 
membr a ne with minimal cellular proliferation. (c) Mesangial glomer· 
ulitis: definite mesangial sclerosis and/or hypercellulari ty involving all 
glomeruli or only a fraction of the glomeruli in either a local or diffuse 
manne r ; usually an increase in the amount of mesangialmatrix accom-
panied by an increased number of mesangial ce lls. 
Laboratory Studies 
T h e fo llowing studies were obtai ned at t he t ime of the ini t ial LBT 
and thr oughout the period of follow-up when clinically warranted: 
comp lete blood count, platelet count, erythrocyte sedimentation rate 
(ESR), VDRL, assay for the third component of complement (C3) and 
total hemolytic complement (CH,.,), ant inuclear ant ibody (ANA) t iter, 
BUN, serum creatinine, microscopic examination of urine sediment, 
24-h uri n a ry protein excretion, and creatinine clearance. Levels of C3 
were determined by immunodiffusion, and CH,,o was measured by 
microtit r ation according to the technique of Nelson et al [1 7]. During 
the initia l years of the study (1971- 1974) ANA t iters were determined 
by indirect immunofluorescence using sections of rat. kidney as the 
substrate [18], and a human tumor KB cell line substrate (Electronu-
cleonics, Columbia, Maryland) after 1975 [1 9). Antibodies to native 
DNA (nDNA) were measured at or near the time of the initial LBT in 
11 patients using the Millipore fil te r assay of Ginsberg and Keiser 
[20]. A n t i-nD NA was determined late r in the study (1976- 1981) using 
the Crit h idia luciliae indirect immunofluorescence assay [21). 
Statistical Calculation,; 
Statistical calcu lations were performed by Chi -square approximation 
(Kruskall -Wallis test) or Fisher's exact test. Survival curves were 
generated by Kaplan-Meier product limit survival analysis and com-
pared by the Breslow statistic. 
SUBEPIDERMAL IMMUNE DEPOSITS IN SLE 
RESULTS 
Serial LET Findings and Effects of Immunosuppressive 
Therapy 
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Examination by direct immunoflu orescence revea led the 
presence of 1 or more immunoglobulin classes a lon g the dermal-
epidermaljunction (positive LBT) in 29 (57%) of 51 init ial skin 
biopsies in t he study group. Immunoglobulin was present most 
commonly in a granular band wi t h thready or stippled patterns 
seen occasionally. Ten patients had only lgM deposi ted at t he 
dermal -epidermal zone. l gG was found a lone or in combination 
with anothe.r immunoglobulin class in t he other 19, with lgG 
and lgM bemg t he most frequent combination . Based on the 
initial LBT, which was uninfluenced by systemic treatment, 
the patients were divided into LET-negative and LET-pos it ive 
groups. A comparison of the two groups revealed n o significant 
diffe rence wi t h regard to sex or race. The two groups were a lso 
comparable in age at diagn osis, number of LBTs, and fo llow-
up s ince init ia l LBT (Table 1). The only s ignificant difference 
was a longer time between diagnosis a nd initial LBT in t he 
LET-negative group. W e suspect t his may have been due to 
relatively milder disease in t his group with delayed refe rra l to 
our medical center. 
A comparison of t he two groups with regard to t reatment is 
shown in T able II. Immunosupp ressive t herapy subsequent to 
t he LBT in this study consisted of e it he r t herapeut ic doses of 
cytotoxic. drugs (u su ally cycloph ospham ide, but occasionally 
azathwprme o ~ chlorambucil) 111 association with tapering 
doses of predm sone or predn isone alone. The instit ution of 
immunosuppressive t herapy and dosage adjustments were 
based on t he clinical judgement of t he attending staff and were 
not randomized. Patients t reated with high-dose prednisone 
(greater tha n 40 mg per day) were included for an alysis with 
the group t reated with cytotoxic drugs. Those patients treated 
wi t h lower doses of p rednisone (no greater t ha n 40 mg per day) 
and no cytotoxic d rugs were assessed separately. 
A total of 223 skin biopsies for direct immunofluorescence 
were obtained in the 51 SLE patients (average, 4.4 per patient). 
The results of 84 seria l biopsies on t he 22 init ially LBT-
TABLE I. Comparison of LET-negative and -positive groups 
Age at diagnosis (years) 
Time between diagnosis 
and ini t ial LBT (years) 
No. of LBTs 
Follow-up since init ial 
LBT (years) 
"Mean± SE. 
• NS = not significant. 
LBT-neg' 
(n = 22) 
35.0 ± 2.6 
4.4 ± 1.4 
3.8 ± 0.3 
8.0 ± 0.6 
LBT·pos• Significance (n = 29) 
31.4 ± 2.9 NSb 
0.4 ± 0.1 p = 0.01 
4.8 ± 0.4 NS 
7.0 ± 0.6 NS 
TABLE II . Compon:son of LBT-negat.ive and -positive groups with 
rega rd to subsequent treatment 
LBT-neg LBT-pos 
Treatment (n = 22) (n = 29) 
% .. ,. 
Cytotoxic" drug and predni- 27 52 
sone 
Prednisone >40 mg (maxi- 50 10 
mum daily dose) 
Prednisone ::-;40 mg (max i- 18 34 
mum daily dose) 
No cytotoxic agent or pred- 5 3 
nisone 
• Cytotoxic drug- usually cyclophosphamide, occasionally azathio-
prine or chlorambucil. 
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negative patients are shown in Fig 1. There were 2 deaths in 
t his group (9%). Seventy-two of 84 (86%) of the LETs were 
negative. There were only 12 positive LETs occurring in 6 
patients. The fo ll owing points can be made regarding these 
patients: 10 of t he 12 LETs were of weak inte nsity; 9 of the 12 
LETs consisted of a single immunoglobulin class (lgG or lgM) ; 
5 of the 12 positive LETs were associated with a clinically 
obvious SLE fl are; and all 6 patients were living at last fo llow-
up. 
In orde r to assess t he effect of immunosuppressive therapy 
on t he LET, the 29 LET-positive patients were subdivided into 
2 groups according to treatment. Fifty-seven serial LETs were 
performed in 11 patients treated with daily doses of prednisone 
no greater than 40 mg and no cytotoxic agents (Fig 2). There 
were 3 deaths in t hi s group during t he study (27%). Although 
5 of the patients had at least 1 negative LET during t he period 
of observation, 49 of t he total 57 determinations (86%) were 
positive. Negative LETs occurred following clinical and sero-
logic evidence of disease remission . 
The effect of high -dose prednisone and/or cytotoxic drugs in 
a group of 18 patients who were LET -positive prior to treat-
ment is illustrated in Fig 3. There were 8 deaths in this group 
(44%). All but 2 of t he patients treated with cytotoxic agents 
became LET -negative. Discontinuation of more aggressive 
therapy was sometimes associated with exacerbation of disease 
and a return to LET positivity. 
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FIG 1. Results of84 serial biopsies on 
22 pretreatment LET-negative SLE pa-
tients. e = LBT-negative; e = LET-
posit ive; d = death. 
FIG 2. Results of 57 serial biopsies on 
11 pretreatment LBT-positive SLE pa-
tients treated with prednisone alone in 
daily doses of no greater than 40 mg. e 
= LET-negative; e = LBT-positive; d = 
death. 
LBT in Relation to Renal Disease 
Table III shows a comparison of the cumulative clinical 
features in the LET-negative and LET-positive groups. The 
only distinguishing feature was a significantly higher (p = 
0.025) prevalence oflupus nephropathy, defined as 24-h urinary 
protein excretion greater than 3.5 g, repeated presence of cel-
lular casts, or creatinine clearance less than 60 ml/min in the 
LET-positive group. 
To further investigate this difference, t he groups were ex-
amined for impairment of renal function as evidenced by ele-
vated serum creatinine. There was no significant difference in 
mean serum creatinine between the two groups at the time of 
the initial LET (0.9 mg/dl and 1.1 mg/dl). To evaluate the 
predictive value of the initial LET, the two groups were com-
pared again using the maximum recorded serum creatinine. 
The mean maximum serum creatinine levels detected in the 
LET-positive patients (3 .0 mg/dl) were significantly higher (p 
< 0.05) than in the LET-negative patients (1.2 mg/dl). Thus, 
a positive LET identified a subset of SLE patients at higher 
risk for deterioration of renal function. 
Table IV provides a comparison of renal histology in the 
LET-negative and -positive groups. Only 1 of 11 (9%) renal 
biopsies in the LET-negative patients revealed changes of 
diffuse proliferative glomerulonephritis, the most severe histo-
logic form of lupus nephritis. This is in marked contrast to 13 
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TABL E III. Compari~;on of cumulativP clinical feature> in the LBT -
negative and -pooitive groups 
LBT- neg LBT-pos 
Cli nica l feaLu re (n = 22) (n = 29) Signitic11nce 
% % 
Cutan eous lupus erythematosus 
Acute 55 48 NS" 
Chron ic scarring 32 28 NS 
Alopecia 82 55 NS 
Photosensit ivity 32 28 NS 
Oral or nasopharyngeal 23 21 NS 
ulcerations 
Rayn a ud's phenomenon 36 38 NS 
Arthrit is 86 72 NS 
Serositis 64 45 NS 
CNS lupus 27 14 NS 
Vascu litis 0 7 NS 
Lupus n ephropathy 23 55 p = 0.025 
• NS = not sign ificant. 
TABLE IV. Comparison of renal histology in LBT -negative and 
-positive groups 
Histologic classiticotion 
Proliferative glomerulonephritis 
Membranous glomerulonep hri tis 
Mesangial glomeruli tis 
Nor mal 
LBT-neg 
(n = 11 ) 
% 
9 
18 
55 
18 
LBT-pos 
( n = 20) 
% 
65 (p = 0.007) 
15 
20 
0 
of 20 (6 5%) biopsies wi th this finding in the LET -posit ive 
patients. Thus, a posit ive pretreatment LET is associated with 
both more severe renal di sease by clinical cri teria a nd more 
severe r e nal disease by histologic cri teria . 
LBT in R elation to Extrarenal Laboratory Features 
The r e were no significant differences in t he cumulative ex-
traren a l laboratory abnormalities in t he LET-negative and 
-positive groups. Abnormal laboratory findin gs were defined as 
follows: anemia in males is a hematocri t less than 42% and 
hemoglo bin less t han 14 gm/ dl, whil e in females anemia is a 
hematocrit less than 37% and hemoglobin less t han 12 gm/ dl ; 
leukop e nia is a white blood count less t han 4000 per mm" on 2 
or more occasions; t hrombocytopenia is a platelet count less 
than 100,000 per mm'1; objective evidence of hemolysis includ -
ing retic ulocytosis; elevated ESR (greater t han 50 mm/ h-
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FIG 4. Comparative survival rates of in itially LBT-neaative (0) and 
LBT-posit ive (e) SLE patients. b 
Westergren); hypocomplementemia (C3 less than 70 mg/dl or 
CHoo less t han 60 hemolytic units); posit ive ANA (titer of at 
least 1:16 us ing rat kidney as substrate or t iter of 1:160 using 
tumor KE cells as substrate); posit ive ant i-nDNA (>2.0 J.Lg 
DNA bound per ml of serum using the Mill ipore filter assay of 
Ginsberg and Keiser. Later in the study [1976-1981 ] a posit ive 
ant i-nDNA was defined as posit ive kinetoplast flu orescence 
wi t h undilu ted test sera using t he Crithidia luciliae indirect 
immunofluorecence assay) . 
LBT in Relation to Outcome 
Combined survival rates of t he 51 SLE patients were 90% at 
5 years and 74% at 10 years. Combined survival rates of t he 
subjects of this report are therefore comparable to t hose of 609 
patients reported by Wallace eta! (22] and 1103 patients in the 
Lupus Survival Study Group [23]. However, an analysis of 
survival in our study patients based on the init ia l LBT revealed 
survival curves of the two groups to be dramatically differe nt 
(Fig 4). T en-year survival from t he t ime of diagnosis is 95% in 
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the LET-negative group as opposed to only 54% in the LET-
positive group. . . . . 
Neither of t he 2 LBT-negat1ve pat1ents d1ed of v1sceral 
invo lvement by SLE. The cause of deat h was bacterial sepsis 
in both cases. In contrast, 8 of t he 11 deaths in the L~'I_' ­
positive patients were directly related to S.LE (lupus nephn.t1s 
in 6 and vasculi t is in 2). In t he remammg 3 LBT-pos1t1ve 
patients, the cause of death was bacterial sepsis in 2 and 
complications of therapy in the other. 
DISCUSSION 
In 1964, Cormane [24] reported that some patie ~ts withSLE 
have immunoglobulins deposited at the dermal-ep1dermal JU.nc-
tion of clinically normal skin (positive LBT). Smce that t1me 
numerous invest igators have confirmed this observation , b~t 
they have been unab le to agree on its clinical and patholog1c 
implications. . 
Pohle and Tuffa nelli [2] first suggested m 1968 that there 
was a relation between t he presence of immunoglobulins in 
normal -appearing skin and renal involvem~nt. In 1971 Burn -
ham and Fine [3] confirmed this observatiOn when they re-
ported kidney involvement to be 3 t im.es more frequent in LET-
pos itive patients t han in LBT -negat1ve patle~ts . By contrast, 
Caperton, Bean, and Dick found no correlatiOn b~tween the 
presence of immune deposits in skin an~ the sev~nty of renal 
disease in 29 SLE patients whom they fo llowed for at least 1 
year or until death [4]. This diffe.rence might ~e a~tributed. to 
patient se lection, since t hey bwps1ed pat1ents w1 t h very active 
and seve re SLE" and included on ly 9 pat1ents who were LBT-
negative. Likewise, Grossman, C~l~erame, and Con.demi [5] 
found no correlation between a pos1tlve LBT and spec1fic organ 
system involvement in 26 patient~, al.though ~heir skin ~i~psies 
were obtained from a vanety of skm Sites and Included chmcally 
normal as well as involved skin . 
In 1974 we [6] reported 42 SLE patients in whom skin 
biopsies were obtai ned exclusively from t he medial volar fore-
arm prior to immunosuppressive. drug therapy. The LB! was 
positive in 70% of patients with chmcal and _laboratory ev1dence 
of renal disease, but in only 31% of pat1ents without renal 
disease. Renal biopsies were obtained in 29 patients and 81 % 
of patients with diffuse proliferative gl?~erulonephritis or 
membranous glomerulonephri t is had pos1t1ve ~~Ts whereas 
on ly 23% of patients with mesangial glomerul~ti s or normal 
renal histology were posit ive. These results agam suggested a 
relation between a positive LBT and the presence of severe 
forms of lupus nephri t is, a conclusion supported by the study 
of Dantz ig et a l (7]. . 
Schrager and Rothfield !8] observed that th.e corre!atwn 
between a positive LBT and t he presence ~f ch.mcal disease 
activity in several orga n systems could be dimm1shed by sys-
tem ic chemotherapy. At t he t ime of their skin biopsies 4~ of 48 
patients were rece iving cort icosteroids, cyclophosphamide, or 
azathioprine. T hi s effect of chemotherapy mak~s the .subse-
quent report of Wertheimer and Barland [9] m .~h1ch no 
significant co rrelat ion was observed between a positive LBT 
and lupus nephriti s in 53 patients easier to interpret. 
Recently 4 independent studies have ind icated that all re-
ports concerning the LBT must be interpreted with great care . 
In 1977 we (11] reported that SLE patients with predominantly 
lgM nO NA-binding activity in t heir serum have less renal 
involvement and longer survival t han t hose with predominantly 
lgG nDNA serum binding activi ty. Furthermore, predominant 
serum lgM nONA -binding activity is associated with LBTs 
containing lgM alone, and predominant IgG nONA-binding 
activity is associated with IgG at t he dermal-epidermal junc-
tion . Morris et a l [13 ] have reported 32 simultaneous skin and 
kidney biopsies in 28 patients wi t h SLE, irrespective of clinical 
renal funct ion. They concluded t hat t he LBT does not correlate 
with clinical or histologic measures of glomerulonephri t is and 
that the LBT is highly variable when perfo rmed seria lly in the 
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same pat ient. In this study the biopsy sites were variable; 20 
were from sun -protected skin of the medial upper arm and 12 
from exposed skin. 
Provost et a! [14] reported 62 unt reated SLE patients in 
whom biopsies were obtained from t he light -exposed extensor 
surface of t he upper forearm . Renal biopsies were obtained 
from 22 patients who had evidence of renal disease. They 
concluded that a negative or pure lgM LBT is infrequently 
associated with clinical evidence of renal disease, in contrast 
to those patients who had lgG present in the LBT. Finally, 
Rothfield and Marino [15] reported 31 pat ients who had biop-
sies of nonlesional deltoid skin at 2 separate times. The number 
of proteins present at t he dermal-epidermal junction was cor-
related only with clinical and serologic disease activity, but 
insufficient information was provided concerning chemother-
apy. 
We concluded from t hese studies that there is general agree-
ment concerning the value of the LBT in establishing a diag-
nosis of SLE, but that the relation between LBT and prognosis 
still remains controversial [3- 15] . To reconci le these observa-
tions we entered 51 consecutive patients with documented SLE 
into a 10-year longitudinal study, taking advantage of conclu -
sions developed in t hese earlier studies. Serial biopsies of skin 
were obtained exclusively from the re latively light-protected 
medial volar forearm. To evaluate the effect of immunosup-
pressive therapy on subepidermal immune deposits in the skin 
patients were examined before treatment and repeatedly there-
after. Several important conclusions can be drawn from our 
observations. F irst, patients with SLE who a re LET-negative 
before treatment usually remai n negative over a 10-year period. 
Moreover, LET-positive patients usually remain positive unless 
treated wi t h cytotoxic agents or prednisone in doses of greater 
than 40 mg per day. And finally, the seve ri ty of renal disease 
correlates significantly with the presence and absence of a 
positive LBT. A positive pretreatment LBT identifies a subset 
of SLE patients with more aggressive clinical disease which is 
confirmed by renal biopsy. Aggressive renal disease is reflected 
eventually in differing 10-year survival rates of the two groups. 
Ten-year survival from the time of diagnosis was 95% in the 
LET-negative group and only 54% in the LET-positive group 
(p = 0.007). No LET-negative patients died of visceral involve -
ment by SLE. By contrast, 8 of the 11 deaths in the LBT-
positive patients were directly related to SLE. These findings 
indicate that a positive LBT obtained before treatment has 
important predictive value identifying a subset of SLE patients 
who all develop more aggressive renal disease as well as signif-
icantly decreased long-term survival. 
The authors wish to thank Kim Green and Marquita Brown for their 
secretarial assistance. 
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